Full Press Release Details
BioVie's NE3107 Demonstrates Potential
Improvements in Motor and Non-motor Symptoms for Parkinson's Disease Patients and May Be Realigning Physiological Processes for
Alzheimer's Patients in Data to be Presented at the International Conference on Alzheimer's and Parkinson's Diseases
from Phase 2a trial in Parkinson's Disease suggest patients treated with NE3107 experienced significant improvements in non-motor
symptoms and motor control while placebo-treated patients worsened
Data from Phase 3 trial in mild to moderate
Alzheimer's Disease suggest NE3107 may have the potential to realign physiological processes in patients consistent with decreased
neurocognitive decline and diseases of aging
Carson City NV, March 1, 2024 - BioVie Inc., (NASDAQ:
BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment
of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International
Conference on Alzheimer's and Parkinson's Diseases 2024 (AD/PD 2024) to be held March 5-9, 2024 in Lisbon, Portugal.
Improvements in non-motor symptoms correlated with improvements
in motor symptoms for Parkinson's Disease patients
The presentation Improvement of Non-Motor Symptoms with NE3107 Adjunctive
to Carbidopa/Levodopa in Patients with Parkinson's Disease: A Phase 2A, Placebo-Controlled Study will be presented at 15:10
GMT on March 9, 2024 and suggest improvements of NE3107-treated patients with non-motor symptoms. These findings complement previously
reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity
of NE3107 that is consistent with data from animal models.
NE3107-treated patients experienced a significant improvement of -2.4
points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson's Disease, whereas placebo patients experienced
a worsening of +1.0 points (p=0.0159). Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259).
More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.
changes for NE3107-treated patients were driven by improvements of -0.87 in fatigue/lack of energy (p= 0.0005) and improvement of -2.91
on the urge to move legs/restlessness in legs (p=0.0036). Placebo patients saw no significant change of -0.39 on fatigue (p=0.1242) and
-0.71 on leg restlessness (p=0.5141).
The new data on non-motor improvements complements previously presented
data1 showing NE3107-treated patients saw a 3+ points advantage compared to placebo on the Part 3 (motor) score of the Motor
Disease Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). In patients younger than 70 years old, the advantage was
over 6 points. Furthermore, 26% of NE3107-treated patients experienced improvement in their ability to move, having Part 3 scores prior
to their first morning dose of carbidopa/levodopa that were equal to or better than Part 3 scores associated with their being in the
"on" state after carbidopa/levodopa treatment at the start of the study, whereas none of the placebo patients
had the similarly improved morning Part 3 scores. The difference was statistically significant (p=0.046).
"These data suggest that NE3107 as adjunct therapy to levodopa
may hold promise in ameliorating specific non-motor symptoms of Parkinson's Disease, particularly in sleep/fatigue and restlessness
of the legs," stated Joseph Palumbo, BioVie's Chief Medical Officer. "These findings extend previously reported improvement
in motor symptoms with NE3107 and demonstrate potential intrinsic and levodopa-enhancing activity of NE3107 that is consistent with data
from animal models and support further clinical investigation of NE3107 in late-phase trials."
Possible physiological realignment in Alzheimer's Disease
The presentation Clinical Outcomes from a Phase 3, Randomized, Placebo-Controlled
Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer's Disease will be presented at 14:50 GMT on March 8, 2024
reconfirms topline cognitive and functional data previously presented and will provide additional biomarker data and analyses.
The NM101 Trial enrolled 439 patients through 39 sites. The Company
previously reported that upon trial completion, significant deviation from protocol and Good Clinical Practice violations were found at
15 sites, causing the Company to exclude all patients from these sites. After these exclusions and other exclusions per the statistical
analysis plan, 57 patients in the Per-Protocol population were verified to have taken study drug from pharmacokinetics data and completed
the full duration of the trial. Baseline and completion data were available for 50 subjects (NE3107, n=24 and placebo, n=26; 7 subjects
randomized to placebo discontinued before day 150), and DNA methylation data were available for 33 subjects in this cohort.
Due to the exclusion of data from so many sites the trial missed statistical
significance but showed promising directional data on cognitive and functional measures. NE3107-treated patients saw an advantage compared
to placebo of -0.95 (68% slowing of decline) on CDR-SB, -0.94 (26%) on ADAS-COG-12, -0.43 (139%) on ADAS-CGIC, -0.03 (27%) on ADCOMS,
+1.02 (40%) on MMSE, and +3.08 (47%) on ADCS-ADL.2
Significant improvements for NE3107-treated patients vs. placebo were
observed for biological age deceleration (-3.87 years, p=0.012), fasting glucose levels (-8.5 mg/dL, p=0.036), cholesterol (-15 mg/dL,
p=0.049), HOMA2 beta cell function (+12.4%, p=0.040), HOMA2 Insulin Sensitivity (+1.95%, p=0.018), and MCP1 (-90.5 pg/mL, p=0.007). Trending
improvements in HOMA2 Insulin Resistance of -0.020 (p=0.0.063) were also observed.
A statistical technique called Principal Component Analysis3
identified neurological assessments and biological age deceleration as the two "principal components" that maximally
explained the data across the large set of variables collected. Among NE3107-treated patients, correlations of neurological assessments
and biological age deceleration with improved metabolic and glycemic control, improved neuropsychiatric indices, and levels of
chemokines associated with microglial attraction to and digestion of A plaques. Among placebo patients, neurological assessments
and biological age deceleration were correlated with increased metabolic inflammatory measures, M1 to M2 transition, and plaque phagocytosis.
"We previously reported that NE3107 appeared to decrease metabolic
inflammation-driven systems dysregulation," stated Chris Reading, BioVie's Senior Vice President of Alzheimer's Disease
Programs. "Principal component analyses, divergent correlations, and epigenetic analysis suggest that metabolic inflammation may
be a driver of biological aging and AD, and that NE3107 might have the potential to realign physiological processes consistent with decreased
neurocognitive decline and diseases of aging."
"The data being presented reinforce our confidence in the potential
of NE3107 to have a meaningful impact on core symptoms of both Alzheimer's disease and Parkinson's disease," stated Cuong Do, BioVie's
President and CEO. "These findings add to the growing body of evidence supporting our hypothesis that by selectively modulating inflammation
and enhancing insulin sensitivity in the brain, NE3107 could offer benefits in slowing disease progression and improving the lives of
patients living with these devastating conditions."
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage
company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling)
that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth
and survival). Both are drivers of Alzheimer's and Parkinson's diseases. The Company conducted and reported efficacy data
from its randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild
to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated
patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer's Disease (CTAD)
annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's. A Phase 2 study of NE3107 in Parkinson's
disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related
Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in "morning on" symptoms
and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated
with levodopa alone, and no drug-related adverse events. In liver disease, the Company's Orphan drug candidate BIV201 (continuous
infusion terlipressin), with U.S. Food and Drug Administration (FDA) Fast Track status, is being evaluated and discussed with guidance
received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis.
The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information,
visit http://www.bioviepharma.com/.
Forward-Looking Statements
This press release contains forward-looking
statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend,"
"plan," "believe," "seek," "estimate," "will," "project" or words of similar
meaning. In this press release, forward-looking statements include, but are not limited to, the potential impact of NE3107 on cognition
and function among study participants and topline data from the NE3107 trial. Although BioVie Inc. believes such forward-looking statements
are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially
from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable
terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends,
our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability
to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional